Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
658
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Alleviation of isolated nail lichen planus by the JAK1/2 inhibitor Baricitinib: a case report

Juan Hea Department of Dermatology, First Medical Center of Chinese PLA General Hospital, Beijing, ChinaORCID Iconhttps://orcid.org/0000-0002-3933-0563View further author information
ORCID Icon,
Tengyu Wenga Department of Dermatology, First Medical Center of Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Wenwei Zhua Department of Dermatology, First Medical Center of Chinese PLA General Hospital, Beijing, ChinaView further author information
,
Yi Yangb Department of Dermatology, The Third Medical Center of the Chinese People’s Liberation Army, Beijing, ChinaCorrespondence[email protected]
View further author information
&
Chengxin Lia Department of Dermatology, First Medical Center of Chinese PLA General Hospital, Beijing, ChinaCorrespondence[email protected]
View further author information
Article: 2274816 | Received 19 Oct 2023, Accepted 19 Oct 2023, Published online: 02 Nov 2023

References

  • Tziotzios C, Lee JYW, Brier T, et al. Lichen planus and lichenoid dermatoses: clinical overview and molecular basis. J Am Acad Dermatol. 2018;79(5):1–3. doi:10.1016/j.jaad.2018.02.010.
  • Goettmann S, Zaraa I, Moulonguet I. Nail lichen planus: epidemiological, clinical, pathological, therapeutic and prognosis study of 67 cases: nail lichen planus. J Eur Acad Dermatol Venereol. 2012;26(10):1304–1309. doi:10.1111/j.1468-3083.2011.04288.x.
  • Gupta MK, Lipner SR. Review of nail lichen planus: epidemiology, pathogenesis, diagnosis, and treatment. Dermatol Clin. 2021;39(2):221–230. doi:10.1016/j.det.2020.12.002.
  • Boch K, Langan EA, Kridin K, et al. Lichen planus. Front Med. 2021;8:737813. doi:10.3389/fmed.2021.737813.
  • Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. doi:10.3389/fimmu.2019.02847.
  • Yang CC, Khanna T, Sallee B, et al. Tofacitinib for the treatment of lichen planopilaris: a case series. Dermatol Ther. 2018;31(6):e12656. doi:10.1111/dth.12656.
  • Seiringer P, Lauffer F, Pilz A, et al. Tofacitinib in hypertrophic lichen planus. Acta Derm Venereol. 2020;100(14):adv00220. doi:10.2340/00015555-3585.
  • Plante J, Eason C, Snyder A, et al. Tofacitinib in the treatment of lichen planopilaris: a retrospective review. J Am Acad Dermatol. 2020;83(5):1487–1489. doi:10.1016/j.jaad.2020.05.104.
  • Damsky W, Wang A, Olamiju B, et al. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. J Allergy Clin Immunol. 2020;145(6):1708–1710.e2. doi:10.1016/j.jaci.2020.01.031.
  • Iorizzo M, Haneke E. Tofacitinib as treatment for nail lichen planus associated with alopecia universalis. JAMA Dermatol. 2021;157(3):352–353. doi:10.1001/jamadermatol.2020.4555.
  • Pünchera J, Laffitte E. Treatment of severe nail lichen planus with baricitinib. JAMA Dermatol. 2022;158(1):107–108. doi:10.1001/jamadermatol.2021.5082.
  • Shao S, Tsoi LC, Sarkar MK, et al. IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci Transl Med. 2019;11(511):eaav7561. doi:10.1126/scitranslmed.aav7561.
  • Di Lernia V. Targeting the IFN-γ/CXCL10 pathway in lichen planus. Med Hypotheses. 2016;92:60–61. doi:10.1016/j.mehy.2016.04.042.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.